# EDmicBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/edmicbio

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.edmicbio.com
- Latest round: Seed (Oct 1, 2020)
- Investors on record: 2

## About

EDmicBio Inc. is a biotechnology company focused on advancing drug discovery and disease treatment through its innovative 3D Organ-on-a-chip technology, which closely replicates human organ systems for more accurate testing.EDmicBio Inc. specializes in developing technology that enhances drug discovery processes. Founded in 2019, the company is headquartered in Seoul, South Korea. It has completed four deals with its most recent funding round occurring on December 22, 2021, where it raised KRW 500.000 mn from POSTECH Holdings, totaling KRW 500.000 mn raised to date. The CEO, Dong-Heon Ha, leads the company, but further details about his prior ventures are not provided.EDmicBio Inc. specializes in the development of 3D Organ-on-a-chip technology, designed to enhance drug discovery and disease treatment processes. This platform enables researchers to create microenvironments that closely mimic human organ systems, facilitating accurate testing of pharmaceutical compounds and therapeutic approaches. The company aims to improve human life quality by providing solutions for effective drug screening while reducing animal testing reliance. Its clientele includes pharmaceutical companies, research institutions, and universities across North America, Europe, and Asia, reflecting a demand for revolutionary healthcare research technologies.EDmicBio generates revenue through the sale of its proprietary 3D Organ-on-a-chip devices and associated services to clients in the pharmaceutical and research sectors. Transactions occur via direct business-to-business partnerships, with clients purchasing devices and services tailored to their research needs. The company's offerings include various models of the Organ-on-a-chip for different organ systems and disease models, crucial for drug testing. Revenue is structured around one-time purchases of these specialized devices and potential ongoing service agreements for technical support and consultation, reflecting the advanced technology and customization of its products, which are positioned as premium solutions in the market.In December 2021, EDmicBio Inc. secured funding to accelerate its market entry through collaborations and validations with medical experts. The company aims to expand its product line with upcoming innovations in 3D Organ-on-a-chip technology, targeting new geographic markets in North America, Europe, and Asia by mid-2023. The recent venture funding will support these initiatives by enhancing collaboration opportunities and validating product effectiveness in diverse healthcare settings.

## Funding rounds

- Seed, Oct 1, 2020 — Korea Tech Incubator for Startup, POSTECH Holdings

## Investors

- Korea Tech Incubator for Startup — Seed
- POSTECH Holdings (https://capitalatlas.ai/funds/postech-holdings) — Seed